Monoket long retard

Quick links

Choose a section

Quick links to important sections

Advertisements
Advertisements

Overview of Monoket long retard

Defining Monoket long retard: Active Substance and Pharmacological Class

Monoket long retard is an oral prescription medication featuring the active ingredient Isosorbide Mononitrate. This substance is categorized as an Organic Nitrate and is recognized as a long-acting Vasodilator Agent. The compound is a synthetic organic derivative of glucitol.

As a single-ingredient product, Isosorbide Mononitrate is utilized for its sustained anti-anginal properties. It is notable within the nitrate class for its high oral bioavailability, differentiating it from early nitrate formulations subject to high first-pass metabolism. This characteristic allows for a consistent therapeutic presence in the body.


Composition and the Extended-Release ("Retard") Formulation

The designation "long retard" specifies the unique extended-release or modified-release form, which is intended for oral administration as a tablet or capsule. This specialized formulation contrasts with immediate-release versions by controlling the rate at which Isosorbide Mononitrate is released over several hours.

This controlled delivery is a key differentiating feature. Such modified-release formulations are designed to provide prolonged therapeutic effect, assisting in the long-term management of circulatory conditions. This sustained action helps ensure that the effect is maintained steadily throughout the dosing interval.


General Therapeutic Purpose and Action Principle

The medication’s general therapeutic purpose is the prophylactic management of conditions caused by an inadequate supply of oxygen to the heart muscle. The underlying principle is vasodilation, which is the widening of blood vessels.

The substance acts as a Nitric Oxide donor, promoting the relaxation of vascular smooth muscle, primarily in the veins. This physiological action reduces the volume of blood returning to the heart, consequently decreasing the heart's overall cardiac workload. By lessening this effort and improving blood circulation, the drug helps to achieve a balance between the heart muscle's oxygen demand and its availability.

Advertisements

What side effects are possible with Monoket long retard?

The safety profile of Isosorbide Mononitrate extended-release is categorized by frequency and organ system based on data collected and published by official regulatory authorities.

Classification of Undesirable Effects

The most commonly documented adverse reactions are typically extensions of the drug's vasodilatory action, appearing primarily in the Nervous System and Vascular Disorders classes:

  • Very Common (Affects 1 in 10 or more): The most frequent reaction documented in regulatory labels is Headache. Official documentation notes that this is most likely to occur at the start of treatment and generally diminishes or resolves after a few weeks of continued therapy.
  • Common (Affects 1 to 10 in 100): Reactions classified as common include Dizziness and Orthostatic Hypotension (a drop in blood pressure when standing up), as well as a reflex increase in heart rate (Tachycardia).
  • Uncommon (Affects 1 to 10 in 1,000): Less frequent events documented include Nausea and Vomiting (Gastrointestinal Disorders), allergic skin reactions like a rash, and rarely, Circulatory Collapse.

High-Level Safety Constraints

Specific high-risk conditions and concomitant drug uses are defined in regulatory labeling. The most serious constraint is the absolute contraindication for co-administration with Phosphodiesterase type 5 (PDE5) inhibitors (e.g., sildenafil) and soluble guanylate cyclase (sGC) stimulators due to the risk of life-threatening Severe Hypotension.

Additionally, caution is advised for patients who are volume depleted or already hypotensive, as the medication may aggravate these conditions. Safety notes also exist for patients with certain heart conditions, such as Hypertrophic Cardiomyopathy, where nitrate therapy may paradoxically increase angina symptoms.

Advertisements

Overdose and Emergency Response

The official regulatory documentation for Isosorbide Mononitrate defines the overdose profile primarily through severe hemodynamic instability, which mandates seeking immediate medical attention. Documented manifestations of overdose include marked hypotension, often leading to syncope, particularly when upright, accompanied by physiological changes such as reduced cardiac output. Clinical signs officially reported include a persistent throbbing headache, confusion, vertigo, palpitations, and visual disturbances, as well as gastrointestinal effects such as nausea, vomiting, and bloody diarrhea. Severe outcomes officially documented in regulatory sources include a potential for increased intracranial pressure and, rarely, the development of Methemoglobinemia.

When an overdose is suspected, official guidance requires seeking immediate emergency medical care. The management strategies described in regulatory documents are primarily supportive, aimed at an increase in central fluid volume. This is commonly achieved through measures such as passive elevation of the patient's legs and intravenous infusion of normal saline. Regulatory warnings explicitly state that the use of epinephrine or other arteriolar vasoconstrictors is likely to do more harm than good in this setting. Furthermore, official labeling notes that fluid expansion therapy poses a specific hazard and requires caution in patients with concurrent renal disease or congestive heart failure, necessitating specialized monitoring.

Advertisements

Therapeutic Uses of Monoket long retard

Monoket long retard (Isosorbide Mononitrate extended-release) is a prophylactic medication generally applied in conditions marked by increased physiological stress. The medicine is commonly used to support continuous management of recurrent symptomatic patterns. The use of this medicine is relevant across therapeutic domains involving distressing symptoms related to coronary artery disease.


Preventing Chronic Angina Pectoris

This medication is commonly used across conditions presenting with recurrent or episodic manifestations, such as stable angina pectoris. It is relevant for easing symptoms that interfere with daily comfort, such as recurrent ischemic chest discomfort. It is commonly used for symptom patterns characteristic of chronic coronary artery disease. This contributes to easing the overall symptom load during periods of heightened symptoms.

It is also relevant in clinical settings involving established coronary heart disease and may be part of symptomatic management as an adjunctive therapy in chronic congestive heart failure (CHF). This supportive role provides support that helps ease the overall symptom burden and may assist with maintaining functional stability during symptomatic phases.

Quick Fact: Relief for Recurrent Ischemic Chest Discomfort

Regulatory References

  1. DailyMed/FDA Overview
Advertisements

Eligibility and Restrictions for Use

Eligibility for Monoket Long Retard

Monoket long retard (Isosorbide Mononitrate extended-release) is primarily intended for adults. Eligibility rules are strictly defined by regulatory contraindications and restrictions.


Eligibility Status Applicable Populations and Conditions
Use is Contraindicated Patients with known hypersensitivity to any nitrate, severe hypotension, acute circulatory failure, or marked anaemia. The medicine is also prohibited for patients concurrently taking Phosphodiesterase type 5 (PDE5) inhibitors (e.g., sildenafil) or the soluble guanylate cyclase (sGC) stimulator riociguat.
Use Requires Caution Patients with certain cardiac conditions, including aortic or mitral valve stenosis and hypertrophic obstructive cardiomyopathy (HOCM). Caution is also advised in patients who are volume depleted or have severe liver or renal disease.
Age-Related Eligibility Pediatric Use: Safety and efficacy have not been established in children. Older Adults (Geriatric): Use is permitted but requires caution due to potential increased sensitivity to hypotensive effects.
Pregnancy and Lactation Use is not recommended or advised only if clearly needed; safety in human pregnancy is not definitively established, and it is unknown if the drug is excreted in human milk.

Regulatory Context: Official prescribing information establishes these constraints, limiting use to stable adult patients and excluding groups where the risk of severe hypotension or other complications is formally documented, such as those on specific co-medications.

Advertisements

What should I know about interactions with other medicines?

The interaction profile for Monoket long retard (Isosorbide Mononitrate extended-release) is strictly defined by prohibitions and risks of additive pharmacological effects, as documented by official government health authorities.

Co-administration is contraindicated with two major classes of vasodilators. These are Phosphodiesterase Type 5 (PDE-5) Inhibitors (including Sildenafil, Tadalafil, and Vardenafil) and Soluble Guanylate Cyclase (sGC) Stimulators (such as Riociguat). This absolute restriction is based on the significant risk of severe, life-threatening hypotension or myocardial ischemia resulting from the extreme potentiation of vasodilatory effects. A minimum of 48 hours must elapse after the last dose of Tadalafil before the administration of this nitrate.

The medicine can engage in additive pharmacodynamic interactions with various other classes of medicines that lower blood pressure. These include Antihypertensives like beta-blockers, ACE inhibitors, calcium channel blockers, and diuretics, where the co-administration may potentiate the hypotensive effect. This risk also extends to certain Psychotropic Agents, specifically neuroleptics and tricyclic antidepressants.

Interaction with Alcohol (Ethanol) is also documented, exhibiting additive vasodilating effects that may lead to severe postural hypotension. Furthermore, official labeling notes a pharmacokinetic interaction with Dihydroergotamine, an ergot alkaloid, where co-administration may increase the blood level and resulting hypertensive effect of Dihydroergotamine.

Advertisements

Mechanism of Action

How Monoket Long Retard Works

1. Activation of the Nitric Oxide Signaling Pathway

Isosorbide Mononitrate acts as a precursor to Nitric Oxide ( NO), a signaling molecule that activates the enzyme Soluble Guanylate Cyclase ( sGC) inside Vascular Smooth Muscle Cells ( VSMC). This molecular interaction initiates the cGMP signaling cascade, which is required for the subsequent change in the cell's contractile state, leading to smooth muscle relaxation.


2. Modulation of Vascular Tone and Venodilation

The activated cGMP cascade alters the muscle cells' internal environment, resulting in the dephosphorylation of Myosin Light Chain ( MLC) and inducing profound relaxation of the vascular smooth muscle, resulting in vasodilation. This physiological effect is particularly pronounced in the peripheral veins, leading to an increase in their capacitance.


3. Reducing Cardiac Preload and Workload

The systemic venodilation leads to an increase in peripheral venous capacity. This shift in blood volume decreases the volume and pressure of blood returning to the heart's ventricles (reduced preload). The reduction in preload decreases the stretch and tension on the heart muscle fibers. This systemic consequence reduces the cardiac workload and the myocardial requirement for oxygen.


4. Mechanistic Limitation: Nitrate Tolerance

A key constraint on this mechanism is nitrate tolerance, a biological process where the NO signaling system can become less responsive after continuous or prolonged exposure to the drug. This reduction in the system's sensitivity to NO diminishes the magnitude of the vasoactive effect during continuous exposure.

Advertisements

Dosage and Administration Information

How to Use Monoket Long Retard: Administration Guidelines

Monoket long retard (Isosorbide Mononitrate Extended-Release) is prescribed for the prophylactic management of conditions, and its use follows specific administration guidelines. The formulation is administered exclusively via the oral route. It is explicitly not indicated for use in aborting an acute episode of chest pain due to its slow onset of action.


Dosing and Schedule

Regimen Feature Guideline
Dosing Frequency Administered once daily.
Timing Dosing is typically scheduled in the morning upon arising.
Starting Dose Usually 30 mg or 60 mg once daily, adjusted based on individual need.
Maximum Dose The maximum recommended daily intake is 240 mg.

This once-daily schedule is a fundamental usage principle designed to ensure a daily drug-free interval, which is essential for minimizing the potential for the development of drug tolerance over time.


Administration Requirements

The extended-release tablet must be swallowed whole with fluid and must not be crushed, chewed, or divided under any circumstances, as this would compromise the controlled release mechanism. The medicine may be taken with or without food.

For older adults, guidelines recommend initiating treatment at the lower end of the dosing range. If a dose is missed by more than 6 hours, the standard procedure is to skip the missed dose entirely and resume the schedule at the next regular time to preserve the critical nitrate-free period.

Advertisements

Recent Clinical Evidence

Recent Clinical Evidence Overview

Monoket long retard contains the active substance isosorbide mononitrate (ISMN), an organic nitrate primarily indicated for the long-term management and prevention of chest pain (angina pectoris) associated with coronary artery disease. It is not used to treat an acute episode of angina because its onset of action is not fast enough.


Efficacy and Antianginal Activity

Controlled clinical trials, including randomized, placebo-controlled studies, have demonstrated antianginal activity following the administration of the extended-release formulation. This activity is assessed primarily through exercise testing, such as treadmill time, which measures the amount of exercise a participant can perform before the onset of pain.

Research has explored the following key outcomes:

  • Exercise Tolerance: Studies evaluated whether the drug was associated with a significant increase in total treadmill time relative to placebo at specific time points (e.g., 4 and 12 hours) after the first dose.
  • Chronic Dosing: In trials up to six weeks, the antianginal effect was sustained at higher doses (e.g., 120 mg and 240 mg), while lower doses (e.g., 30 mg and 60 mg) were sometimes no longer differentiable from placebo after several weeks of chronic dosing.
  • Nitrate Tolerance: Consistent with the pharmacology of nitrates, dosing regimens are designed to include a nitrate-free interval to help prevent the development of tolerance, which can diminish the antianginal effect over time.

Pharmacokinetics and Tolerability

Bioequivalence studies have been conducted comparing the extended-release formulation to reference products in healthy volunteers under both fasting and fed conditions. These studies reported that the formulations were comparable in how the drug was absorbed and processed by the body.

In clinical studies, the extended-release tablets were generally well tolerated, with headache being the most frequently reported adverse event, a common effect associated with nitrate compounds.

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Monoket long retard (FAQ)

Q: Can I take this medication with my blood pressure pills?

A: Official regulatory documents list specific medications that may interact with this drug, including certain types of blood pressure treatments. Regulatory documents state that interactions with certain medicines, including some blood pressure treatments, may necessitate clinical monitoring or dosage adjustments. It is important to consult the full prescribing information for specific interaction risks.

Q: Does this medication cause sleepiness or affect my ability to drive?

A: Official guidance indicates that undesirable effects, such as dizziness or somnolence (sleepiness), which affect the central nervous system, may occur with this medicine. The regulatory documents caution that the medicine may affect the ability to operate machinery or drive.

Q: How should I store the medication, and what is the shelf life?

A: The official product information provides clear instructions regarding the required storage conditions, such as the approved temperature range and protection from light or moisture. This is necessary to maintain the product's effectiveness and is defined alongside the approved shelf life in the regulatory text.

Q: Can I give this medication to my child who is 4 years old?

A: The regulatory documents specify the approved age range and corresponding dosing for the pediatric population. Only this labeled use is authorized. Use outside the labeled pediatric age range is not covered by the official prescribing information.

Q: What is the mechanism of action of this drug?

A: Regulatory documents explicitly define the mechanism of action, which describes the specific biological pathways or targets that the active substance influences to produce its therapeutic effect.

Q: How long will the drug stay in my system?

A: The regulatory documents contain pharmacokinetic data, including the drug's elimination half-life. The half-life is a scientific measurement that indicates how long it takes for the concentration of the drug in the body to decrease by half. This scientific measurement is part of the drug’s pharmacokinetic data found in the official product information.

Q: Can this drug be taken long-term?

A: The official information on the duration of treatment is provided in the Dosage and Administration section. While regulatory documents report the frequency of side effects observed during clinical trials, this data is limited to the study durations. Information on long-term safety is typically inferred from the duration of clinical trials described in the Adverse Reactions section.

Advertisements

How should Monoket long retard be stored and disposed of?

Storage and Disposal Information

Monoket long retard (Isosorbide Mononitrate Extended-Release) must be stored under specific environmental conditions as defined by regulatory labeling.

Storage Requirements

Condition Requirement
Temperature Store at controlled room temperature, typically 15 C to 30 C (59 F to 86 F).
Protection Keep away from excess heat, moisture, and direct light. Do not freeze.
Packaging Store in the original container with the cap tightly closed.
Child Safety Must be kept out of the sight and reach of children in a secure location.

Disposal Instructions

Do not keep outdated medicine or medicine that is no longer needed. To properly dispose of unused or expired Monoket long retard, individuals must consult a healthcare professional or pharmacist for guidance on local pharmaceutical waste protocols, as disposal via household trash or wastewater is not the default method.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Monoket long retard found in:

A-Z Index: